SCHEMBL12803495

SCHEMBL12803495

OC[C@H]1O[C@@H](n2cnc3c(O)ncnc32)[C@H](OCc2cccnc2)[C@@H]1O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADORA2A P29274 6/20 0.59
▸ ADORA3 P0DMS8 5/20 0.59
▸ ADORA1 P30542 5/20 0.59
▸ SLC29A1 Q99808 5/20 0.53
▸ STAT6 P42226 2/20 0.48
▸ TP53 P04637 1/20 0.48
▸ TDP1 Q9NUW8 1/20 0.48
▸ NFKB1 P19838 1/20 0.47
▸ THPO P40225 1/20 0.47
▸ TSHR P16473 1/20 0.47
▸ DPP4 P27487 1/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ SLC28A1 O00337 1/20 0.46
▸ MAP3K7 O43318 1/20 0.46
▸ SLC28A2 O43868 1/20 0.46
▸ GAPDH P04406 1/20 0.46
▸ MAPK1 P28482 1/20 0.46
▸ ADORA2B P29275 1/20 0.46
▸ PI4KA P42356 1/20 0.46
▸ KMT2A Q03164 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12803497 1.00 ADORA2A (0.59) ADORA2AADORA3ADORA1SLC29A1STAT6
SCHEMBL2220562 0.90 SLC29A1 (0.65) ADORA2AADORA3ADORA1SLC29A1STAT6
SCHEMBL2220567 0.90 SLC29A1 (0.65) ADORA2AADORA3ADORA1SLC29A1STAT6
SCHEMBL2218916 0.89 SLC29A1 (0.54) ADORA2AADORA3ADORA1SLC29A1STAT6
SCHEMBL2218911 0.89 SLC29A1 (0.54) ADORA2AADORA3ADORA1SLC29A1STAT6
SCHEMBL12803364 0.86 SLC29A1 (0.51) ADORA2AADORA3ADORA1SLC29A1STAT6
SCHEMBL12803361 0.86 SLC29A1 (0.51) ADORA2AADORA3ADORA1SLC29A1STAT6
SCHEMBL2220833 0.84 ADORA1 (0.58) ADORA2AADORA3ADORA1SLC29A1STAT6
SCHEMBL2220825 0.84 ADORA1 (0.58) ADORA2AADORA3ADORA1SLC29A1STAT6
SCHEMBL2221601 0.84 SLC29A1 (0.52) ADORA2AADORA3ADORA1SLC29A1STAT6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8877439-B2 Method for rapidly evaluating performance of short interfering RNA with novel chemical modifications SIRNA THERAPEUTICS, INC. (US) 2014-11-04 — — US claimed
US-9512426-B2 Method for rapidly evaluating performance of short interfering RNA with novel chemical modifications SIRNA THERAPEUTICS, INC. (US) 2016-12-06 — — US disclosed
US-20150132761-A1 METHOD FOR RAPIDLY EVALUATING PERFORMANCE OF SHORT INTERFERING RNA WITH NOVEL CHEMICAL MODIFICATIONS BANK OF AMERICA, N.A. 2015-05-14 — — US disclosed
US-8877439-B2 Method for rapidly evaluating performance of short interfering RNA with novel chemical modifications SIRNA THERAPEUTICS, INC. (US) 2014-11-04 — — US disclosed
US-20120252027-A1 Method For Rapidly Evaluating Performance Of Short Interfering RNA With Novel Chemical Modifications BANK OF AMERICA, N.A. 2012-10-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120252027-A1 Method For Rapidly Evaluating Performance Of Short Interfering RNA With Novel Chemical Modifications NSUN2, NSUN3, SNRPE ADORA2A 615/4885ADORA3 728/4885ADORA1 1080/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback